Syndax Pharmaceuticals (SNDX) Enterprise Value (2016 - 2025)
Syndax Pharmaceuticals (SNDX) has 11 years of Enterprise Value data on record, last reported at -$154.5 million in Q4 2025.
- For Q4 2025, Enterprise Value rose 5.83% year-over-year to -$154.5 million; the TTM value through Dec 2025 reached -$154.5 million, up 5.83%, while the annual FY2025 figure was -$154.5 million, 5.83% up from the prior year.
- Enterprise Value reached -$154.5 million in Q4 2025 per SNDX's latest filing, up from -$436.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$57.5 million in Q1 2023 and bottomed at -$455.2 million in Q2 2025.
- Average Enterprise Value over 5 years is -$214.6 million, with a median of -$161.1 million recorded in 2024.
- Peak YoY movement for Enterprise Value: plummeted 333.01% in 2022, then surged 69.53% in 2023.
- A 5-year view of Enterprise Value shows it stood at -$222.2 million in 2021, then soared by 62.67% to -$83.0 million in 2022, then crashed by 264.41% to -$302.3 million in 2023, then surged by 45.71% to -$164.1 million in 2024, then grew by 5.83% to -$154.5 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$154.5 million in Q4 2025, -$436.0 million in Q3 2025, and -$455.2 million in Q2 2025.